Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336
Hazard Ratio01:12

Hazard Ratio

108
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
108

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same author

Improved Colloidal Stability and Phase Transfer of Gold Nanoparticles with Bidentate Dendritic Ligands.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registry.

Urology practice·2026
Same author

When the Platform Owns the Procedure: Intellectual Property Rights and Robotic Surgery.

European urology·2026
Same author

Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer.

Genes and immunity·2026
Same author

Beyond the Policy Cliff: Preserving Telemedicine for the Future.

The Journal of urology·2026
Same journal

The International Medical Graduate Paradox.

Annals of surgery·2026
Same journal

Defining the Incremental Value of Endoscopic Ultrasound in Assessing Pancreatic Cystic Neoplasms.

Annals of surgery·2026
Same journal

Trends in Metabolic and Bariatric Surgery and GLP-1 Receptor Agonist Use Among Adolescents with Severe Obesity.

Annals of surgery·2026
Same journal

The Ambulatory Surgery Center Paradox: Why 60% of Surgeries Occur Where 2% of AI Research Happens.

Annals of surgery·2026
Same journal

Medical Student First Authorship in High-Impact Surgical Journals: Longitudinal Trends and Institutional Concentration, 2000-2025.

Annals of surgery·2026
Same journal

Radial Margin Distance in Perihilar Cholangiocarcinoma: Defining Dual Cutoff Values of 0 and 1 mm.

Annals of surgery·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

244

A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven

Nestor F Esnaola1,2, Raju Chelluri2, Jason Castellanos2

  • 1Department of Surgery, Houston Methodist Hospital, Houston, TX.

Annals of Surgery
|July 24, 2024
PubMed
Summary
This summary is machine-generated.

Risk-based management did not reduce death or serious complications after major cancer surgery. This approach also showed no improvements in patient outcomes or healthcare use compared to usual care.

More Related Videos

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.0K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Related Experiment Videos

Last Updated: Jun 19, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

244
A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.0K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Area of Science:

  • Oncology
  • Surgical Care
  • Patient Outcomes

Background:

  • Major cancer surgery presents significant perioperative risks.
  • These risks can negatively impact long-term patient outcomes.

Purpose of the Study:

  • To assess if risk-based, protocol-driven management reduces 30-day death or serious complications (DSCs) after elective major cancer surgery.
  • To compare this intensive management strategy against usual care.

Main Methods:

  • 1529 adult patients undergoing elective major cancer surgery were randomized.
  • Patients received either risk-based management or usual care.
  • Primary outcome was the 30-day rate of DSC; secondary outcomes included complications, survival, and quality of life.

Main Results:

  • The 30-day DSC rate was 15.0% with risk-based management versus 14.1% with usual care (P=0.65).
  • No significant differences were observed in complications, adverse events, length of stay, discharge to home, readmissions, or antineoplastic therapy receipt.
  • Long-term overall survival and disease-free survival were also similar between groups.

Conclusions:

  • Risk-based, protocol-driven management did not lower 30-day DSC rates after major cancer surgery compared to usual care.
  • The intervention did not improve postoperative healthcare utilization, quality of life, or cancer outcomes.
  • Further research is needed to find cost-effective, tailored perioperative strategies for optimizing outcomes in these patients.